flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Preventing chronic disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global (KDIGO) Controversies Conference Semaglutide in kidney outcomes Obesity

These medications belong to a class known as GLP-1 receptor agonists, which work by mimicking natural hormones that regulate appetite, digestion, and blood sugar levels

potential long-term risks include pancreatitis, gallbladder disease, lean muscle loss, and early worsening of diabetic retinopathy, though no confirmed causal links exist beyond 48 weeks of data

Personalized Medical Weight Loss Programs Tailored to Your Needs In Carlsbad, losing weight consistently can be challenging

Clinical trial programs in both diabetic and nondiabetic subjects have reported significant weight loss over sustained periods of once-weekly semaglutide administration [5, 6, 7, 9]

It is important to distinguish between true fluid retention (oedema) and other phenomena that might be mistaken for it